abs269.txt	the	us	food	and	drug	administration	and	the	critical	path	institute'spatient-reported	outcome	(pro)	consortium	convened	a	cosponsored	workshop	on	theuse	of	pro	measures	to	inform	the	assessment	of	safety	and	tolerability	in	cancerclinical	trials		a	broad	array	of	international	stakeholders	involved	in	oncologydrug	development	and	pro	measurement	science	provided	perspectives	on	the	role	ofpro	measures	to	provide	complementary	clinical	data	on	the	symptomatic	sideeffects	of	anticancer	agents		speakers	and	panelists	explored	the	utility	ofinformation	derived	from	existing	and	emerging	pro	measures		focusing	on	the	proversion	of	the	national	cancer	institute's	common	terminology	criteria	foradverse	events		panelists	and	speakers	discussed	potential	ways	to	improve	thecollection		analysis		and	presentation	of	pro	data	describing	symptomatic	adverseevents	to	support	drug	development	and	better	inform	regulatory	and	treatmentdecisions		workshop	participants	concluded	the	day	with	a	discussion	of	possibleapproaches	to	the	patient-reported	assessment	of	an	investigational	drug'soverall	side	effect	burden	as	a	potential	clinical	trial	end	point		the	food	anddrug	administration	reiterated	its	commitment	to	collaborate	with	internationaldrug	development	stakeholders	to	identify	rigorous	methods	to	incorporate	thepatient	perspective	into	the	development	of	cancer	therapeutics	
